Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality

NCT02811198 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 97

Last updated 2026-02-27

No results posted yet for this study

Summary

The ultimate aim of this study is to identify a biomarker of suicide risk in MDD by measuring the "hedonic spectrum" (pain and reward responsivity), attention and its associated brain structures using brain scans (fMRI and DTI), as well as the stability of markers over time.

Conditions

Interventions

OTHER

No intervention

Sponsors & Collaborators

  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Sakina Rizvi, PhD · Unity Health Toronto

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2024-12-09
Completion
2025-01-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02811198 on ClinicalTrials.gov